Scope
NICE guideline NG33, Tuberculosis, covers TB prevention, latent and active TB, drug-resistant TB, infection control, case finding, adherence and service organisation. The source includes recommendations dated from 2006 to 2016, with later amendments, including one to neonatal BCG eligibility in 2024. This summary focuses on clinical decisions: BCG eligibility, latent TB testing in different age and risk groups, latent TB regimen choice and liver precautions, and investigation of pulmonary and extrapulmonary disease. It also covers standard and CNS treatment durations, dosing frequency, adjunctive corticosteroids, rifampicin-resistance testing, reintroduction after hepatotoxicity, isolation, contact screening and directly observed therapy.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
BCG vaccination
- In high-incidence areas, primary care organisations should consider vaccinating all neonates soon after birth. In low-incidence areas, they should offer BCG to selected neonates who were born in a high-incidence area or have a parent or grandparent born in a high-incidence country. [1]
- Offer BCG to Mantoux-negative new entrants from high-incidence countries who are previously unvaccinated, meaning they lack adequate documentation or a BCG scar. Eligible ages are younger than 16 years, or 16 to 35 years if from sub-Saharan Africa or a country with an incidence of 500 per 100,000 or more. [1]
- Offer BCG to Mantoux-negative, previously unvaccinated contacts of pulmonary or laryngeal TB who are aged 35 years or younger. Contacts aged 36 years and older are eligible if they are healthcare or laboratory workers with contact with patients or clinical materials. [1]
- Some people are identified for BCG through occupational health, contact tracing or new entrant screening. If they are also considered at increased risk of HIV, offer an HIV test before vaccination. [1]
Diagnosing latent TB
- Offer Mantoux testing to close contacts aged 18 to 65 of people with pulmonary or laryngeal TB. Refer inconclusive results to a TB specialist. Treat induration of 5 mm or more, regardless of BCG history, as positive and assess for active TB. If active TB is excluded, an IGRA may be considered when more evidence is needed to decide on treatment. If the Mantoux is positive and any IGRA done is also positive, offer latent TB treatment. [1]
- For severely immunocompromised adults, offer an IGRA plus a concurrent Mantoux test. Examples are HIV with a CD4 count below 200 cells/mm3, or after solid organ or allogeneic stem cell transplant. For other immunocompromised adults, consider an IGRA alone or with a Mantoux test. If either test is positive (Mantoux 5 mm or more), assess for active TB. If that assessment is negative, offer latent TB treatment. [1]
- In children and young people, consider an IGRA alone only if Mantoux testing is unavailable or impractical. Offer Mantoux testing to close contacts aged 2 to 17 years of pulmonary or laryngeal TB. If the test is positive (5 mm or more) and active TB is excluded, offer treatment. If the initial test is negative, offer an IGRA after 6 weeks and repeat the Mantoux test. Refer children under 2 who are close contacts of smear-negative disease to a specialist to decide the testing strategy. [1]
- This applies to neonates in close contact with smear-positive pulmonary or laryngeal TB where the source case has not had at least 2 weeks of treatment. First assess for active TB. Then start isoniazid with pyridoxine and do a Mantoux test after 6 weeks of treatment. If the test is positive (5 mm or more) and reassessment excludes active TB, continue isoniazid with pyridoxine for 6 months in total. If it is negative, reassess and consider an IGRA. A negative IGRA means stopping isoniazid and pyridoxine and giving BCG. A positive IGRA means reassessing for active TB and, if that assessment is negative, continuing isoniazid with pyridoxine for 6 months in total. [1]
- Mantoux testing is the initial test for recent arrivals from high-incidence countries who present to healthcare services, with an IGRA if Mantoux is unavailable. Offer a single IGRA to people younger than 65 from under-served groups. In incidents needing large-scale screening, consider a single IGRA for people aged 18 to 65. [1]
Managing latent TB
- This applies to people younger than 65, including those with HIV, with latent TB after close contact with drug-sensitive pulmonary or laryngeal TB. Offer either 3 months of isoniazid (with pyridoxine) plus rifampicin, or 6 months of isoniazid (with pyridoxine). Base the choice on clinical circumstances. Offer the 3-month regimen to people under 35 when hepatotoxicity is a concern after assessing liver function and risk factors. Offer the 6-month regimen when rifamycin interactions are a concern, such as in people with HIV or a transplant. [1]
- For adults aged 35 to 65, offer latent TB treatment only if hepatotoxicity is not a concern. Before treatment, offer HIV testing, and offer adults hepatitis B and C testing. Consider hepatitis B and C testing in children and young people. [1]
- For severe liver disease, such as Child-Pugh B or C, work with a specialist team experienced in TB and liver disease. Treat cautiously, with careful liver monitoring, in the following groups: non-severe liver disease, abnormal baseline liver function including transaminases, and alcohol or drug misuse. [1]
Diagnosing active TB
- When clinical features are consistent with TB, start treatment without waiting for culture results. Completing the standard regimen may be considered even if later cultures are negative. [1]
- For suspected pulmonary TB, take a chest X-ray and investigate further if it suggests TB. Send 3 deep cough sputum samples, preferably including 1 early morning sample, for microscopy and culture. Collect these before treatment where possible; failing that, in people with life-threatening disease, collect them within 7 days of starting. Use spontaneously produced deep cough sputum if possible. Otherwise, use 3 gastric lavages or 3 sputum inductions in children and young people, and sputum induction or bronchoscopy with lavage in adults. [1]
- In adults with clinically suspected TB disease, request rapid nucleic acid amplification tests on primary specimens if any of these apply: the person has HIV, rapid species information would change care, or a large contact-tracing exercise is being considered. Offer these tests to children aged 15 or younger with suspected pulmonary TB. Apply the adult criteria to young people aged 16 to 18. [1]
- Never place TB culture samples in formalin or another fixative. Keep extrapulmonary TB in mind even when rapid tests on CSF, pleural or ascitic fluid are negative. Offer a chest X-ray and, where possible, respiratory culture to look for coexisting pulmonary disease. Offer CT or MRI when CNS involvement is suspected. Treat TB meningitis when clinical and laboratory findings fit, even if a rapid test is negative. [1]
Treating active and drug-resistant TB
- For active TB without CNS involvement, offer isoniazid (with pyridoxine), rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 4 months. For CNS TB, offer the same four drugs for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 10 months. Adjust either regimen according to drug susceptibility testing. [1]
- Use fixed-dose combination tablets. Offer daily dosing for pulmonary TB, and consider daily dosing first for extrapulmonary TB. Do not use regimens of fewer than 3 doses weekly. Consider thrice-weekly dosing only when risk assessment shows a need for directly observed therapy and enhanced case management and daily observed therapy is not possible. [1]
- At the start of treatment for CNS TB, offer dexamethasone or prednisolone at a high initial dose, withdrawn gradually over 4 to 8 weeks. For adults with pericardial TB, offer oral prednisolone starting at 60 mg/day, withdrawn gradually 2 to 3 weeks after starting. [1]
- For people with clinically suspected TB, a TB specialist should request rapid nucleic acid amplification tests for rifampicin resistance on primary specimens if a multidrug-resistance risk assessment finds any risk factor. Risk factors are previous TB treatment (especially with known poor adherence), contact with a known multidrug-resistant case, or birth or residence in a country where WHO reports 5% or more of new cases are multidrug-resistant. Start infection control measures. [1]
- If the rapid test for rifampicin resistance is positive, continue infection control until pulmonary or laryngeal disease has been excluded. Manage treatment with a multidisciplinary team experienced in multidrug-resistant TB, offer a regimen of at least 6 drugs to which the organism is likely sensitive, and test for second-line drug resistance. [1]
- In people whose treatment was interrupted because of drug-induced hepatotoxicity, investigate other causes of the liver reaction. Wait until AST or ALT is below twice the upper limit of normal, bilirubin is normal and symptoms have resolved. Then reintroduce each drug sequentially at full dose over no more than 10 days, starting with ethambutol plus either isoniazid (with pyridoxine) or rifampicin. Do not reuse a drug that causes a similar or worse reaction; consider extending the regimen. [1]
Infection control, contacts and adherence
- Place people with suspected infectious or confirmed pulmonary or laryngeal TB in a single room if they will remain in a hospital setting, including emergency, outpatient or inpatient care. Admit suspected or known infectious multidrug-resistant TB to a negative pressure room. Some people have a continuing need for admission with pulmonary TB. If they are unlikely to be rifampicin resistant, or have negative rifampicin resistance on nucleic acid amplification test or culture, give single-room care, as a minimum, until they complete 2 weeks of standard treatment. Inpatients should wear a surgical mask outside their room until they have had at least 2 weeks of treatment. [1]
- Offer screening to close contacts of pulmonary or laryngeal TB, and assess symptomatic contacts for active disease. For asymptomatic contacts younger than 65, consider standard latent TB testing. For those older than 65, consider a chest X-ray if not contraindicated. Social contacts, including most workplace contacts, are not assessed routinely. [1]
- Allocate a named TB case manager within 5 days of diagnosing active TB. Offer directly observed therapy within enhanced case management to listed groups. These include people with poor adherence now or in the past, previous TB treatment, homelessness or substance misuse, imprisonment now or within 5 years, multidrug-resistant TB, or illness too severe to self-administer. [1]
Limitations and use
- Based on the recommendations chapter only; research recommendations, rationale and impact, update history and committee chapters were not reviewed.
- Flowcharts and visual algorithms were available only as alternative text, and downloadable algorithms were not reviewed.
- This summary is selective. Detailed site-specific investigation tables, paediatric corticosteroid dosing (deferred to BNF for Children), single-drug-resistance regimens, prison and school contact tracing, and service organisation and commissioning recommendations are not fully reproduced.
- Recommendations are written for the NHS in England and refer to UK bodies and resources (Green Book, Public Health England, UK incidence definitions). Some Mantoux recommendations carry a January 2016 note that no licensed Mantoux preparation was then available.
- Recommendations date from 2006 to 2016, with later amendments. Individual recommendation dates and strength wording (offer versus consider) should be checked in the source.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Tuberculosis
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 13 January 2016
- Publisher’s latest update
- 16 February 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.